Prospective single-arm neuroimaging study in 26 overweight/obese adults receiving semaglutide 1.0 mg weekly for 24 weeks, assessing structural and functional MRI changes in the brain alongside metabolic and cognitive assessments. Semaglutide produced neuroprotective changes in left temporal lobe structure and function alongside cardiometabolic improvement. Provides multimodal neuroimaging evidence for semaglutide's regional brain effects—contributing to the mechanistic understanding of GLP-1 RA neuroprotection in at-risk populations and informing biomarker selection for future neurodegenerative disease trials.
Meng, Fanhua; Ao, Xiang; Lin, Xiangming; Li, Yue; Zhang, Rui; Yu, Zhiyan; Zang, Shufei; Sun, Tiange